SG Americas Securities LLC Grows Position in Merck & Co., Inc. $MRK

SG Americas Securities LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 0.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,665,520 shares of the company’s stock after buying an additional 6,529 shares during the period. SG Americas Securities LLC owned 0.07% of Merck & Co., Inc. worth $200,345,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the 4th quarter worth $26,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter worth $31,000. Finally, High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. UBS Group upped their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Stock Up 1.4%

MRK stock opened at $115.47 on Tuesday. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The stock has a market capitalization of $285.19 billion, a PE ratio of 32.53, a price-to-earnings-growth ratio of 2.56 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a fifty day moving average of $115.79 and a 200-day moving average of $113.79.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business posted $2.22 earnings per share. The business’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.